PA
ZNTL icon

Parallel Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Parallel Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-581
Closed -$16K – 3537
2022
Q2 		$16K Buy
581
+22
+4% +$583 ﹤0.01% 1776
2022
Q1 		$25K Hold
559
– – ﹤0.01% 1630
2021
Q4 		$47K Buy
+559
New +$43.3K ﹤0.01% 1361

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Parallel Advisors's ZNTL Position: Q3 2022 in Review

Parallel Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2022, closing a stake of 581 shares — an estimated $16K sold.

Parallel Advisors first reported a position in ZNTL in Q4 2021 and held it in 3 quarters. The position peaked at $47K in Q4 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q3 2022.

  • Parallel Advisors reported no remaining Zentalis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Parallel Advisors sold 581 Zentalis Pharmaceuticals shares in Q3 2022, an estimated $16K.
  • Parallel Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Parallel Advisors's Zentalis Pharmaceuticals position peaked at $47K in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2022.

Based on Parallel Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.